The last one, C5 (21% of all DLBCL) comprises ABC DLBCL cases with BCL2 gains, concordant MYD88 L265P/CD79B plus additional lesions such as gains of 3q, 19q13.42 and inactivation of PRDM1. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.